Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.
C R Benedict, … , P Tijburg, D Stern
C R Benedict, … , P Tijburg, D Stern
Published November 1, 1991
Citation Information: J Clin Invest. 1991;88(5):1760-1765. https://doi.org/10.1172/JCI115495.
View: Text | PDF
Research Article Article has an altmetric score of 9

Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.

  • Text
  • PDF
Abstract

To assess the contribution of Factor IX/IXa, to intravascular thrombosis, a canine coronary thrombosis model was studied. Thrombus formation was initiated by applying current to a needle in the circumflex coronary artery. When 50% occlusion of the vessel developed, the current was stopped and animals received an intravenous bolus of either saline, bovine glutamyl-glycyl-arginyl-Factor IXa (IXai), a competitive inhibitor of Factor IXa assembly into the intrinsic Factor X activation complex, bovine Factor IX, or heparin. Animals receiving saline or Factor IX developed coronary occlusion due to a fibrin/platelet thrombus in 70 +/- 11 min. In contrast, infusion of IXai prevented thrombus formation completely (greater than 180 min) at doses of 460 and 300 micrograms/kg, and partially blocked thrombus formation at 150 micrograms/kg. IXai attenuated the accumulation of 125I-fibrinogen/fibrin at the site of the thrombus by approximately 67% (P less than 0.001) and resulted in approximately 26% decrease in serotonin release from platelets in coronary sinus (P less than 0.05). Hemostatic variables in animals receiving IXai, remained within normal limits. Animals given heparin in a concentration sufficient to prevent occlusive thrombosis had markedly increased bleeding, whereas heparin levels that maintained extravascular hemostasis did not prevent intracoronary thrombosis. This suggests that Factor IX/IXa can contribute to thrombus formation, and that inhibition of IXa participation in the clotting mechanism blocks intravascular thrombosis without impairing extravascular hemostasis.

Authors

C R Benedict, J Ryan, B Wolitzky, R Ramos, M Gerlach, P Tijburg, D Stern

×

Total citations by year

Year: 2022 2020 2016 2015 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1995 1994 1993 1992 Total
Citations: 1 1 2 1 1 3 3 2 2 4 1 2 6 4 5 6 4 3 3 4 1 4 3 2 2 70
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (70)

Title and authors Publication Year
Factor IX(a) inhibitors: an updated patent review (2003-present).
Afosah DK, Ofori E, Mottamal M, Al-Horani RA
Expert Opinion on Therapeutic Patents 2022
Immunodiagnostic Technologies from Laboratory to Point-Of-Care Testing
P Suman, P Chandra
2020
Translation and Clinical Development of Antithrombotic Aptamers
SM Nimjee, TJ Povsic, BA Sullenger, RC Becker
Nucleic Acid Therapeutics (Formerly Oligonucleotides) 2016
Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism
S Devabhakthuni, CH Yoon, KJ Pincus
Journal of Pharmacy Practice 2016
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
AM Lincoff, R Mehran, TJ Povsic, SL Zelenkofske, Z Huang, PW Armstrong, PG Steg, C Bode, MG Cohen, C Buller, P Laanmets, M Valgimigli, T Marandi, V Fridrich, WJ Cantor, B Merkely, J Lopez-Sendon, JH Cornel, JD Kasprzak, M Aschermann, V Guetta, J Morais, PR Sinnaeve, K Huber, R Stables, MA Sellers, M Borgman, L Glenn, AI Levinson, RD Lopes, V Hasselblad, RC Becker, JH Alexander
The Lancet 2015
Vascular Medicine: A Companion to Braunwald's Heart Disease
P Libby
Vascular Medicine: A Companion to Braunwald's Heart Disease 2013
Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism
Y Buyue, TM Misenheimer, JP Sheehan
Journal of Thrombosis and Haemostasis 2012
The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome
JP Vavalle, MG Cohen
Future Cardiology 2012
Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates
WJ van Rensburg, JP Roodt, S Lamprecht, SM Meiring, PN Badenhorst
Clinical and Experimental Medicine 2012
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
H Ulrichts, K Silence, A Schoolmeester, P Jaegere, S Rossenu, J Roodt, S Priem, M Lauwereys, P Casteels, FV Bockstaele, K Verschueren, P Stanssens, J Baumeister, JB Holz
Blood 2011
Factor IXa as a Target for Pharmacologic Inhibition in Acute Coronary Syndrome
C Roser-Jones, M Chan, EL Howard, KC Becker, CP Rusconi, RC Becker
Cardiovascular Therapeutics 2011
Annual Reports in Medicinal Chemistry
JJ Liu, TW Lee
Annual Reports in Medicinal Chemistry Volume 46 2011
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli
Burger's Medicinal Chemistry and Drug Discovery 2010
xPharm: The Comprehensive Pharmacology Reference
A Vinh
xPharm: The Comprehensive Pharmacology Reference 2010
Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite
Y Buyue, JP Sheehan
Blood 2009
Cardiovascular disease in patients with hemophilia
A Tuinenburg, EP Mauser-Bunschoten, MC Verhaar, DH Biesma, RE Schutgens
Journal of Thrombosis and Haemostasis 2009
Fundamental and Clinical Cardiology Series
PD Stein
Cardiovascular Disease in the Elderly 2008
Anticoagulant therapy during cardiopulmonary bypass
M Yavari, RC Becker
Journal of Thrombosis and Thrombolysis 2008
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
MY Chan, CP Rusconi, JH Alexander, RM Tonkens, RA Harrington, RC Becker
Journal of Thrombosis and Haemostasis 2008
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study
BI Eriksson, OE Dahl, MR Lassen, DP Ward, R Rothlein, G Davis, AG Turpie
Journal of Thrombosis and Haemostasis 2008
Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies
D Luan, M Zai, JD Varner, S Miyano
PLoS computational biology 2007
The status of new anticoagulants
SM Bates, JI Weitz
British Journal of Haematology 2006
Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism
JP Sheehan, EN Walke
Blood 2006
New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin
SM Bates, JI Weitz
British Journal of Pharmacology 2005
New anticoagulants
JI Weitz, SM Bates
Journal of Thrombosis and Haemostasis 2005
5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa
JX Qiao, X Cheng, DP Modi, KA Rossi, JM Luettgen, RM Knabb, PK Jadhav, RR Wexler
Bioorganic & Medicinal Chemistry Letters 2005
Structure-based design and synthesis of pyrazinones containing novel P1 ‘side pocket’ moieties as inhibitors of TF/VIIa
BA Schweitzer, WL Neumann, HK Rahman, CL Kusturin, KR Sample, GI Poda, RG Kurumbail, AM Stevens, RA Stegeman, WC Stallings, MS South
Bioorganic & Medicinal Chemistry Letters 2005
The coagulation factor lottery – Is 9 the winning number?
GZ Feuerstein, D Stern
Drug Discovery Today: Therapeutic Strategies 2005
The Factor IXa Heparin-Binding Exosite Is a Cofactor Interactive Site: Mechanism for Antithrombin-Independent Inhibition of Intrinsic Tenase by Heparin
QP Yuan, EN Walke, JP Sheehan
Biochemistry 2005
Anticoagulant drugs: an update
HC Kwaan, MM Samama
Expert Review of Cardiovascular Therapy 2004
The impact of vitamin K-dependent factor depletion by warfarin on platelet-rich thrombosis after deep arterial injury
RD Mcbane, NL Hassinger, DE Grill, JH Chesebro
Journal of Thrombosis and Haemostasis 2004
Antidotes to haemorrhage: recombinant factor VIIa
CM Kessler
Best Practice & Research Clinical Haematology 2004
The Future of Anticoagulation
PP Dobesh, K Kim, Z Stacy
Journal of Pharmacy Practice 2004
Current anticoagulant therapy—unmet clinical needs
J Hirsh
Thrombosis Research 2003
Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation
K Kitazato, KT Kitazato, E Sasaki, K Minamiguchi, H Nagase
Thrombosis Research 2003
Inhibition of arterial thrombosis by polyamines in a canine coronary artery injury model
R Pakala
Thrombosis Research 2003
New Anticoagulants: Current Status and Future Potential
JI Weitz, MA Crowther
American Journal Cardiovascular Drugs 2003
Heparin Inhibits the Intrinsic Tenase Complex by Interacting with an Exosite on Factor IXa
JP Sheehan, CE Kobbervig, HM Kirkpatrick
Biochemistry 2003
Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke
JR Toomey, RE Valocik, PF Koster, MA Gabriel, M McVey, TK Hart, EH Ohlstein, AA Parsons, FC Barone
Stroke; a journal of cerebral circulation 2002
Antithrombotic agents in the treatment of severe sepsis
H Shadid, S Aziz, S Ahmad, J Fareed, D Hoppensteadt, H Messmore, W Wehrmacher, M Tobu, O Iqbal
Expert Opinion on Emerging Drugs 2002
Overview of anticoagulant drugs for the future
S Moll, HR Roberts
Seminars in Hematology 2002
Effect of polyamines on in vitro platelet aggregation and in vivo thrombus formation
R Pakala
Cardiovascular Radiation Medicine 2002
A Human Antibody That Inhibits Factor IX/IXa Function Potently Inhibits Arterial Thrombosis Without Increasing Bleeding
CJ Refino, S Jeet, L DeGuzman, S Bunting, D Kirchhofer
Arteriosclerosis, thrombosis, and vascular biology 2002
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model
I Singh, A Smith, B Vanzieleghem, D Collen, K Burnand, JM Saint-Remy, M Jacquemin
Blood 2002
Emerging anticoagulant and thrombolytic drugs
O Iqbal, S Aziz, DA Hoppensteadt, S Ahmad, JM Walenga, M Bakhos, J Fareed
Expert Opinion on Emerging Drugs 2001
Factor IX and thrombosis
GD Lowe
British Journal of Haematology 2001
New Anticoagulant Drugs
JI Weitz, J Hirsh
Chest 2001
New anticoagulant drugs
J I Weitz
Journal of Thrombosis and Thrombolysis 2001
Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis
JR Toomey, MN Blackburn, BL Storer, RE Valocik, PF Koster, GZ Feuerstein
Thrombosis Research 2000
Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase
JA Anderson, JC Fredenburgh, AR Stafford, YS Guo, J Hirsh, V Ghazarossian, JI Weitz
The Journal of biological chemistry 2000
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism
JE Ansell, JI Weitz, AJ Comerota
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2000
Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage
TF Choudhri, BL Hoh, CJ Prestigiacomo, J Huang, LJ Kim, AM Schmidt, W Kisiel, ES Connolly, DJ Pinsky
Journal of Experimental Medicine 1999
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats
GZ Feuerstein, A Patel, JR Toomey, P Bugelski, AJ Nichols, WR Church, R Valocik, P Koster, A Baker, MN Blackburn
Arteriosclerosis, thrombosis, and vascular biology 1999
Antithrombotics
AC Uprichard, KP Gallagher
1999
THERAPEUTIC INHIBITION OF THROMBIN ACTIVITIES, RECEPTORS, AND PRODUCTION
LA Harker
Hematology/Oncology Clinics of North America 1998
Management of Bleeding Complications in Redo Cardiac Operations
CR MD
The Annals of Thoracic Surgery 1998
Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass
T B Spanier, J M Chen, M C Oz, N M Edwards, W Kisiel, D M Stern, E A Rose, A M Schmidt
The Journal of Thoracic and Cardiovascular Surgery 1998
Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog
T B Spanier, M C Oz, O P Minanov, R Simantov, W Kisiel, D M Stern, E A Rose, A M Schmidt
The Journal of Thoracic and Cardiovascular Surgery 1998
Textbook of Coronary Thrombosis and Thrombolysis
RC Becker
1997
Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal
PR Eisenberg
Journal of Thrombosis and Thrombolysis 1995
Calreticulin, an Antithrombotic Agent Which Binds to Vitamin K-dependent Coagulation Factors, Stimulates Endothelial Nitric Oxide Production, and Limits Thrombosis in Canine Coronary Arteries
K Kuwabara, DJ Pinsky, AM Schmidt, B Benedict, B Brett, S Ogawa, MJ Broekman, AJ Marcus, RR Sciacca, M Michalak, F Wang, YC Pan, G Grunfeld, P Patton, T Malinski, DM Stern, J Ryan
The Journal of biological chemistry 1995
New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA
CR Benedict, CJ Refino, BA Keyt, R Pakala, NF Paoni, GR Thomas, WF Bennett
Circulation 1995
Active Site–Blocked Factors VIIa and IXa Differentially Inhibit Fibrin Formation in a Human Ex Vivo Thrombosis Model
D Kirchhofer, TB Tschopp, HR Baumgartner
Arteriosclerosis, thrombosis, and vascular biology 1995
Macromolecular Complex Assembly of Prothrombinase Is a Central Process of Thrombosis
U Sinha, S Hollenbach, DL Wolf
Annals of the New York Academy of Sciences 1994
Endothelial-dependent procoagulant and anticoagulant mechanisms. Recent advances in understanding
CR Benedict, R Pakala, JT Willerson
Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 1994
Platelet membrane-mediated coagulation protease complex assembly
SS Ahmad, PN Walsh
Trends in Cardiovascular Medicine 1994
High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury
JK Mickelson, PT Hoff, JW Homeister, JC Fantone, BR Lucchesi
Journal of the American College of Cardiology 1993
Enhancement of recombinant tissue plasminogen activator-induced reperfusion by recombinant tick anticoagulant peptide, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis
MJ Mellott, MT Stranieri, GR Sitko, II Stabilito, JJ Lynch, GP Vlasuk
Fibrinolysis 1993
Calreticulin
M Michalak, RE Milner, K Burns, M Opas
Biochemical Journal 1992
Expression, purification, and characterization of inactive human coagulation factor Xa (Asn322Ala419)
U Sinha, TE Hancock, PH Lin, S Hollenbach, DL Wolfs
Protein Expression and Purification 1992

← Previous 1 2 3 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 10 patents
15 readers on Mendeley
See more details